Studies with GFP-Vpr fusion proteins: induction of apoptosis but ablation of cell-cycle arrest despite nuclear membrane or nuclear localization  by Waldhuber, Megan G et al.
Studies with GFP-Vpr fusion proteins: induction of apoptosis
but ablation of cell-cycle arrest despite nuclear
membrane or nuclear localization
Megan G. Waldhuber,a,b,c Michael Bateson,b,c Judith Tan,d
Alison L. Greenway,b and Dale A. McPheea,b,c,*
a Department of Microbiology, Monash University, Clayton, Victoria, 3168, Australia
b AIDS Cellular Biology Unit, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, 3004, Australia
c National Centre for HIV Virology Research, Melbourne, Victoria, 3004, Australia
d Faculty of Medicine, University of Melbourne, Parkville, Victoria, 3052, Australia
Received 20 November 2003; accepted 17 March 2003
Abstract
The human immunodeficiency virus type 1 (HIV-1) Vpr protein is known to arrest the cell cycle in G2/M and induce apoptosis following
arrest. The functions of Vpr relative to its location in the cell remain unresolved. We now demonstrate that the location and function of Vpr
are dependent on the makeup of fusion proteins and that the functions of G2/M arrest and apoptosis are separable. Using green fluorescence
protein mutants (EGFP or EYFP), we found that fusion at either the N- or C-terminus compromised the ability of Vpr to arrest cell cycling,
relative to that of His-Vpr or wild-type protein. Additionally, utilizing the ability to specifically identify cells expressing the fusion proteins,
we confirm that Vpr can induce apoptosis, but appears to be independent of cell-cycle arrest in G2/M. Both N- and C-terminal Vpr/EYFP
fusion proteins induced apoptosis but caused minimal G2/M arrest. These studies with Vpr fusion proteins indicate that the functions of Vpr
leading to G2/M arrest and apoptosis are separable and that fusion of Vpr to EGFP or EYFP affected the localization of the protein. Our
findings suggest that nuclear membrane localization and nuclear import and export are strongly governed by modification of the N-terminus
of Vpr.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) encodes
a series of proteins from the structural and regulatory genes
gag, env, pol, tat, and rev, to the accessory genes vpr, vif,
vpu, and nef. The accessory proteins are not essential for
HIV-1 replication in vitro; however, they do play an impor-
tant role in modulating the virus life cycle in vivo (Cullen
and Greene, 1990; Trono, 1995). The accessory gene vpr
encodes a 96 amino acid, 15-kDa protein. Vpr is packaged
into viral particles (Yuan et al., 1990) through an interaction
with the p6 region of the Pr55Gag precursor protein (Kondo
and Gottlinger, 1996; Lavallee et al., 1994; Lu et al., 1995;
Mahalingam et al., 1997; Paxton et al., 1993; Sato et al.,
1996). Vpr is reported to be dispensable for virus replication
in human T cell lines and primary CD4 lymphocytes, but
is important for infection of monocytes and macrophages
(Akari et al., 1992; Balliet et al., 1994; Cohen et al., 1990;
Connor et al., 1995; Dedera et al., 1989). The role of Vpr in
translocation of the viral preintegration complex (PIC) into
the nucleus of the newly infected cell (Heinzinger et al.,
1994) and transactivation of the HIV-1 LTR is important in
infection of such nondividing cells (Agostini et al., 1996;
Vanitharani et al., 2001).
In several studies, Vpr has been shown to accumulate in
the nuclei of infected and transfected cells (Di Marzio et al.,
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1995; Lu et al., 1993; Mahalingam et al., 1995; Zhao et al.,
1994). There have been two major regions of Vpr identified
to be involved in nuclear localization (Jenkins et al., 1998).
The first is the N-terminal -helix encompassing residues
17 to 34 (Mahalingam et al., 1995; Yao et al., 1995). The
second region comprises residues 53 to 78, that can also
form an -helix (Schuler et al., 1999). Expression of Vpr
causes an arrest of cell cycling and the subsequent accumu-
lation of cells in the G2/M phase of the cell cycle (Jowett et
al., 1995; Rogel et al., 1995). Vpr is conserved among the
primate lentiviruses (Planelles et al., 1996) and has been
shown to arrest cell cycling in both mammalian and yeast
cells (Zhang et al., 1997; Zhao et al., 1996). Conservation of
both Vpr and its manipulation of the host cell alludes to the
potential key role Vpr plays in the life cycle of HIV-1.
Vpr has been implicated in both the induction (Jacotot et
al., 2000; Shostak et al., 1999; Stewart et al., 1997, 1999,
2000) and the prevention (Conti et al., 1998; Fukumori et
al., 1998) of apoptosis. In some studies, Vpr-mediated ap-
optosis has been shown to be dependent on the induction of
G2/M arrest (Stewart et al., 1997; Watanabe et al., 2000;
Yao et al., 1998). The family of caspases comprises the
effector arm of apoptosis, and Vpr has been shown to induce
the activation of a number of these proteins (Patel et al.,
2000; Stewart et al., 2000). The function of Vpr, in regard
to apoptosis, may be either induction or inhibition depen-
dent upon the level of expression, subcellular location, and
possibly other factors present in the cell.
Understanding the localization of Vpr relative to its func-
tions may provide insight into potential cellular partners for
the execution of these functions. Indeed, HIV-1 Vpr has
been studied as a GFP C-terminal fusion protein in terms of
localization and/or function with different outcomes noted
(Sherman et al., 2001; Zhu et al., 2001). To further define
the localization and function of HIV-1 Vpr, the enhanced
green or yellow fluorescent proteins (EGFP or EYFP, re-
spectively) derivatives of GFP from the jelly fish Aequorea
victoria were chosen as both N- and C-terminal fusion
partners. A large number of studies have demonstrated the
innocuous behavior of GFP as a fusion partner (Doyle and
Botstein, 1996; Stearns, 1995; Straight et al., 1997; West-
phal et al., 1997). However, any concerns relating to the
functional integrity of a GFP-fusion protein are readily
addressed by functional analysis of both N- and C-termi-
nally tagged constructs (Kaech et al., 1996). EGFP has been
used extensively in mammalian expression systems as a
marker of transfection efficiency and to determine subcel-
lular localization of fused proteins (Chalfie et al., 1994;
Wang and Hazelrigg, 1994). The subcellular localization of
proteins fused to EGFP or EYFP can also be studied without
distribution variation due to fixation procedures (Brock et
al., 1999).
Hence, to assess the subcellular localization and function
of HIV-1 Vpr, we constructed both N- and C-terminal
EGFP or EYFP fusion proteins with Vpr and also used Vpr
and/or a His-tagged protein as controls. Subcellular local-
izations were determined in three cell lines by confocal
microscopy, and the function of the proteins was assessed
by examining their effects on cell cycling and apoptosis. We
show that both Vpr fusion proteins were unable to signifi-
cantly arrest cells in G2/M compared with Vpr or His-Vpr,
whereas all four proteins caused apoptosis in HeLa cells.
Additionally, fusion of EGFP or EYFP to the N- or
C-terminus of Vpr had a dramatic effect on cellular local-
ization.
Results
Level of transfection efficiency and expression of EGFP
and Vpr fusion proteins by flow cytometry
The mammalian cell lines 293T, 293, and HeLa were
transiently transfected with pEGFP, pEGFP-Vpr, or pVpr-
EGFP. Analysis by flow cytometry was used to determine
the percentage of cells transfected and level of protein
expression (Fig. 1). The transfection efficiency of the vari-
ous plasmids ranged from 45 to 99% of the gated popula-
tions in the three cell lines. A bimodal distribution of fluo-
rescence was evident for EGFP expression alone in all three
cell types. This distribution corresponded to populations of
high and low relative fluorescence. The bimodal distribution
of relative fluorescence was not as obvious for both Vpr
fusion proteins in all cell types. High transfection efficien-
cies were consistently achieved, suggesting that most of the
Fig. 1. Transient transfection of pEGFP, pEGFP-Vpr, or pVpr-EGFP in
293T, 293, or HeLa cells as measured by FACS analysis. Cells were
assessed at 48 h posttransfection. Each sample transfected with EGFP or an
EGFP fusion protein is shown in gray relative to the mock-transfected cells
(vector alone), shown in black. Gates marked were set according to cells
transfected with pEN-1.
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population was expressing the Vpr fusion proteins to sig-
nificant levels (Fig. 1). A point to note is that the fluores-
cence intensity was consistently lower for the Vpr fusion
proteins than EGFP alone, particularly for HeLa cells. This
is important in terms of the possible effects of Vpr on the
level of expression and for coincident analyses of Vpr-
positive populations.
Confirmation of protein expression by immunoblotting
To verify the expression of EGFP, EGFP-Vpr, Vpr-
EGFP, and His-Vpr, transiently transfected cells were lysed
and analyzed by immunoblotting (Fig. 2). Preliminary time-
course experiments in 293T cells indicated 24 to 48 h
posttransfection was optimal for peak expression of these
proteins (Fig. 2A). A polyclonal antibody directed against
GFP and/or Vpr detected bands corresponding to EGFP-Vpr
or Vpr-EGFP (Fig. 2A) that were 42 to 43 kDa in size.
EGFP-Vpr was consistently found to be marginally smaller
in molecular weight than Vpr-EGFP. Sequence analysis of
the two plasmids indicated that the expressed fusion pro-
teins should be identical in size (data not shown). The size
difference and detection was consistent in all three cell
types tested (Figs. 2A, B, and C). The EGFP-Vpr and
Vpr-EGFP proteins were also detected with a polyclonal
antibody directed against amino acids 2 to 21 of Vpr (Figs.
2B and C, lanes 5–8). This antibody also detected the
15-kDa His-tagged Vpr (Fig. 2D), albeit weakly. On occa-
sion we also observed a breakdown product of EGFP-Vpr
with the anti-Vpr; this represented 10% of the total pro-
tein. Expression levels of the fusion proteins were consis-
tently greater than His-tagged Vpr despite equivalent DNA
input in the transfections.
Localization of Vpr fusion proteins in 293T, 293, and
HeLa cells
The localization of EGFP, EGFP-Vpr, and Vpr-EGFP
proteins in the three cell lines was determined by confocal
microscopy (Fig. 3A). The EGFP protein was distributed
throughout the cell in all cell lines, although there was some
exclusion from nucleoli and cytoplasmic vacuoles. The lo-
calization of EGFP-Vpr was principally (90%) in the
nuclei of transfected HeLa, 293, and 293T cells. Clear
exclusion from the nucleoli and some accumulation at the
nuclear membrane was also evident (Fig. 3A, g–i). Strik-
ingly, expression of Vpr-EGFP resulted in a very different
pattern, with the fusion protein predominantly (90%) lo-
calized to the nuclear membrane (Fig. 3A, d–f). There was
also some protein observed in the nuclei of cells expressing
Vpr-EGFP, albeit less compared with EGFP-Vpr, and no-
tably there were intense foci of fluorescence in the cyto-
plasm of transfected cells (approximately 40%). Localiza-
tion of each of the fusion proteins in the three different cell
types was similar. The expression levels of the proteins of
Fig. 2. Immunoblotting of Vpr fusion protein expression. Cells were
transiently transfected with pEGFP, pEGFP-Vpr, pVpr-EGFP, pHis-Vpr,
or mock-transfected. At 24 (A) and 48 h (A–D) posttransfection, 293T (A),
293 (B), or HeLa (C) cells were lyzed and analyzed by electrophoresis and
immunoblotting with anti-GFP (A, lanes 1–5, B, lanes 1–4, and C, lanes
1–4) or anti-Vpr antibody (A, lanes 6–8, B, lanes 5–8, C, lanes 5–8, and
D, lanes 1–3). C and D were transferred from a 15% PAGE gel compared
with 12% for A and B. The lower band observed in C, lane 8 represented
10% of the total product and was only observed occasionally.
Fig. 3. (A) Subcellular localization of EGFP fusion proteins by confocal microscopy. 293T, 293, or HeLa cells were transiently transfected with pEGFP,
pVpr-EGFP, or pEGFP-Vpr. At 48 h posttransfection cells were viewed by confocal microscopy using a 60 objective. Representative sections (0.2 to 0.5
m) of the expressed proteins are shown. (B) Hoechst staining of transfected HeLa cells.HeLa cells were mock-transfected (pEN-1)(a) or transfected with
Vpr-EGFP (b and c). At 72 h posttransfection, the DNA of the cells was stained using Hoechst 33342. The cells were viewed and photographed with a Zeiss
fluorescent microscope using a 40 objective. The Hoechst staining is shown in blue (a and c), while the green fluorescence of Vpr-EGFP is shown in green
(b). Please note the EGFP is as viewed by fluorescence microscopy and not by confocal microscopy, hence viewing the whole cell rather than a cross-section
as shown in A. The arrows denote cells with fragmented DNA, indicative of apoptotic cells.
93M.G. Waldhuber et al. / Virology 313 (2003) 91–104
94 M.G. Waldhuber et al. / Virology 313 (2003) 91–104
Fig. 4. (A) Subcellular localization of His-tagged Vpr. 293T, 293, and HeLa cells were transiently transfected with pHis-Vpr. At 48 h posttransfection cells
were incubated with either a polyclonal antibody to Vpr (a, c, e, and g) or a monoclonal anti-His antibody (b, d, f, and h). Mock-transfected HeLa cells were
used as a control (g and h). The secondary antibody in each case was conjugated to FITC. Representative thin sections (0.2 m) of the subcellular localization
patterns observed by confocal microscopy using a 60 objective are shown. (B) Comparison of localization of Vpr and Vpr fusion proteins in permeabilized
and non permeabilized 293T cells. Cells were transiently transfected with pHis-Vpr (a and b), pVpr-EGFP (c and d), or pEGFP-Vpr (e and f). At 48 h
posttransfection, cells were fixed with 3.5% paraformaldehyde, permeabilized with methanol:acetone (1:1), followed by staining for immunofluorescence with
anti-Vpr antibodies (a and b), fixed with 3.5% paraformaldehyde (c and e), or fixed with 3.5% paraformaldehyde followed by permeabilization with
methanol:acetone (1:1) (d and f). Typical representations of the subcellular localization were recorded using confocal microscopy using a 60 objective.
Fig. 5. Kinetics of subcellular localization of Vpr EYFP fusion proteins in HeLa cells by confocal microscopy using a 60 objective are shown.
Representative thin sections (0.2 to 0.5 m) of the subcellular localization patterns observed 24, 48, and 72 h posttransfection are shown.
interest were greater by both fluorescence and immunoblot-
ting in 293 and 293T cells (Figs. 2 and 3A). Nuclear mem-
brane localization was confirmed by coincidental staining
with nucleoporin p62 in the three cell types (data not
shown). Permeabilizing the cells for detection of p62 pro-
tein altered the distribution of the EGFP fusion proteins in
that they appeared more diffuse.
Localization of His-Vpr in 293T, 293, and HeLa cells
The structure of EGFP is cylindrical and very compact.
However, it is still a relatively large fusion partner of 28
kDa. The pHis-VprNL expression plasmid provided a source
of HIV-1 Vpr with a small, 6 amino acid histidine tag.
Localization of His-tagged Vpr protein in 293T, 293, and
HeLa cells was also examined by confocal microscopy (Fig.
4A). Antibodies directed against Vpr (amino acids 2 to 21)
or the His-tag specifically detected the expressed protein.
The protein was found to localize predominantly in the
region of the nuclear membrane; however, fluorescence was
diffuse in comparison to expression of the fusion proteins.
The pattern of cellular expression was the same using both
anti-Vpr and anti-His antibodies. Permeabilization of the
cells resulted in a more diffuse fluorescence as demon-
strated by a direct comparison to Vpr-EGFP using the same
conditions. Distribution was also altered with more protein
observed in the cytoplasm (Fig. 4B). The fluorescence pat-
tern was much more diffuse, very similar to that observed in
cells transfected with His-VprNL (Fig. 4B, a and b). Strik-
ingly, cells expressing EGFP-Vpr that were fixed exhibited
almost complete nuclear localization compared to perme-
abilized cells which showed additional cytoplasmic staining
(Fig. 4B, e and f). Cellular morphology was also not as well
defined in permeabilized cells. We also did coincident
Hoechst staining on occasion, further confirming predomi-
nant nuclear localization and also fragmented nuclei, indic-
ative of apoptosis (Fig. 3B).
Kinetics of the distribution of Vpr fusion proteins
Using this defined in situ localization technique, we next
followed the kinetics of localization of the Vpr fusion pro-
teins. Additionally, we also compared EYFP fusion proteins
with those of EGFP for subsequent coincident apoptosis
analyses of transfected cells. First, we found that the pattern
of fluorescence was very similar among equivalent EGFP or
EYFP Vpr fusion constructs and in the three cell types over
the 72 h tested (data not shown). Representative results for
Vpr-EYFP and EYFP-Vpr in transfected HeLa cells at 24,
48, and 72 h posttransfection are detailed in Fig. 5. Kinetic
studies revealed a change in the distribution over time for
both Vpr fusion proteins. After nuclear membrane localiza-
tion of Vpr-EYFP by 48 h, there was subsequently an
increased amount of expressed protein accumulating in cy-
toplasmic foci, predominantly in perinuclear regions (com-
pare Figs. 5a, b, and c). This predominant perinuclear lo-
calization increased from 20% at 24 h to 50% at 72 h
posttransfection. Cytoplasmic foci, although present earlier,
were not necessarily perinuclear nor as prominent.
For EYFP-Vpr, nuclear localization was observed but
there were also focal areas of fluorescence in both the
nucleus and the cytoplasm (Figs. 5d and e). Similar to the
C-terminal fusion proteins, these fusion proteins also in-
creasingly aggregated in the perinuclear region with faint
nuclear membrane localization by 72 h posttransfection
(Fig. 5f).
Effect of Vpr fusion proteins and His-Vpr on cell cycling
Extensive studies have shown that HIV-1 Vpr is able to
induce G2/M arrest in multiple cell types (Goh et al., 1998;
Jowett et al., 1995; Poon et al., 1998; Rogel et al., 1995).
We assessed the functional integrity of the Vpr fusion pro-
teins in comparison to constructs expressing HIV-1 Vpr or
His-Vpr. Experiments were performed in the three cell types
used in the localization studies. While we were unable to
reproducibly demonstrate significant G2/M arrest in either
293 or 293T cells with the control Vpr plasmids (Vpr or
His-Vpr; data not shown), we were clearly able to see G2/M
arrest in HeLa cells by these proteins when compared to
controls (Fig. 6).
HeLa cells transiently transfected with pEGFP, pEYFP,
pEGFP-Vpr, pVpr-EGFP, pEYFP-Vpr, pVpr-EYFP,
pcDNA3.1 Vpr, and His-Vpr were stained with propidium
iodide and the DNA content of the cells was analyzed by
flow cytometry (Fig. 6). The percentage of gated cells in
G0/G1 and G2/M were measured and the ratios of G2/M:
G0/G1 were calculated. Except for the mock-transfected
samples, gates were set to include only those cells that were
positive for EGFP or EYFP expression. Cells expressing
Vpr or His-Vpr resulted in a significant accumulation of
cells in G2/M, with a G2/M:G0/G1 ratio of 1 by 72 h
posttransfection (Fig. 6). In comparison to mock-transfected
cells, those expressing EGFP (data not shown) or EYFP
alone showed similar values to the negative control. This
was also the case for pcDNA3.1VprR73S, a mutant atten-
uated in its ability to arrest cells in G2/M (Sawaya et al.,
2000). In contrast to cells accumulating in G2/M for Vpr or
His-Vpr, the fusion constructs all showed the reverse. HeLa
cells appeared transiently arrested in G2/M early posttrans-
fection (24 h), but this reduced over time to the extent that
it was even less than the EYFP controls by 72 h posttrans-
fection (Fig. 6). Results in 293 and 293T transfected cells
were equivocal, but there appeared to be a similar effect
albeit less pronounced (data not shown).
Vpr fusion proteins induce apoptosis in transfected HeLa
cells
Propidium iodide staining of 293T, 293, and HeLa cells
transfected with pEGFP, pVpr-EGFP, or pEGFP-Vpr and
analyzed for DNA content 24 to 72 h posttransfection re-
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vealed there was an increase in the sub-G0 population for
those expressing Vpr-EGFP and EGFP-Vpr (data shown for
72 h posttransfection; Table 1). There was little change in
the percentage of cells in the sub-G0 population for 293T
cells with the exception of those cells transfected with
pEGFP-Vpr and pHis-Vpr (Table 1). This and the cell-cycle
arrest data prompted a more definitive study in HeLa cells.
As expression and location of Vpr EYFP and EGFP
fusion proteins were shown to be very similar in all cell
types tested, an apoptotic marker (Caspase 3) that was
readily quantifiable with EYFP-transfected cells by FACS
analysis was selected to assess coincident apoptosis. Results
of PI or Hoechst staining demonstrated that 72 h was opti-
mal for detection of cell death (data not shown). The selec-
tion of CaspACE FITC-VAD-FMK (CaspACE)—a rela-
tively late marker of apoptosis—was based on previous
studies (Muthumani et al., 2002; Stewart et al., 2000) which
showed that apoptosis induced by HIV-1 Vpr required
caspase activation. Transfected cells were analyzed for
staining by CaspACE by flow cytometry, and the percent-
age of positively stained cells in the EYFP-positive popu-
lation was used to measure apoptotic transfected cells (see
Fig. 7A for representative flow cytometric cell distribution).
Analysis revealed that 0.9 and 14.9% of the mock-trans-
fected and EYFP-transfected populations, respectively,
were apoptotic (Fig. 7B). CaspACE-positive cells express-
ing Vpr and His-Vpr comprised 28.8 and 24.5%, respec-
tively, of the transfected population, while VprR73S dem-
onstrated no ability over transfected controls to induce
apoptosis, with 8.5% of cells apoptotic. In fact this value
was even lower than that of EYFP-transfected cells. In
contrast, 51.2 and 49.0% of Vpr-EYFP- and EYFP-Vpr-
expressing cells, respectively, were CaspACE positive, in-
dicating significantly increased apoptosis in cells expressing
either fusion protein. In comparison, the positive controls
(cells treated with 2.5 and 5 g/ml of Actinomycin D)
showed slightly higher levels of apoptosis, with 51.3 and
60.8% of cells, respectively, staining positive for CaspACE.
By this caspase 3 staining method, reduced levels of
apoptosis were observed in 293 and 293T cells, when com-
pared with HeLa cells (data not shown). The level of apo-
ptosis in EYFP-transfected cells obscured any effect of
these Vpr constructs in causing cell death and suggested that
much of the induced apoptosis observed was due to trans-
fection with DNA or the calcium phosphate transfection
process itself.
In HeLa cells, Vpr and His-Vpr consistently demon-
strated similar abilities to induce apoptosis, indicating that
the histidine tag had no dramatic effect on this Vpr function.
Vpr fusion proteins were also consistent in their abilities to
induce markedly higher levels of apoptosis, with almost a
100% increase in the number of apoptotic cells compared
with cells expressing Vpr or His-Vpr. This approximated
the levels achieved by treatment of cells with the drug
Actinomycin D.
Fig. 6. Cell-cycling profiles for HeLa cells transfected with EYFP, EGFP/EYFP-Vpr, Vpr-EGFP/EYFP, Vpr with EYFP, or His-Vpr with EYFP. HeLa cells
were transiently transfected with pEYFP, pEGFP-Vpr, pEYFP-Vpr, pVpr-EGFP, pVpr-EYFP, pVpr, or pHis-Vpr. Cells were fixed and stained with
propidium iodide 24, 48, and 72 h posttransfection and the DNA content of the cells were analyzed by flow cytometry. The ratio of cells in G2/M:G0/G1 is
shown. Results are the mean and SD from three separate experiments.
Table 1
Vpr induced apoptosis (percentage sub-G0 population)
Plasmid 293T 293 HeLa
pEN-1 2.7  0.9 13.0 5.9 6.3 5.6
pEGFP () 2.3  0.9 18.3 5.4 4.0 1.6
pEGFP () 2.7  0.5 11.0 3.7 6.7 5.3
pVpr-EGFP () 3.0 0.8 29.0 3.3 28.7 7.9
pVpr-EGFP () 2.3 0.5 9.3 3.3 7.7 4.5
pEGFP-Vpr () 5.3 0.5 27.0 5.1 19.0 3.3
pEGFP-Vpr () 3.3 0.5 10.0 3.7 7.0 2.9
pHis-Vpr 6.0 0.5 13.0 3.5 11.0 3.2
Note. Averaged from three experiments (SD).
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Fig. 7. (A) Flow cytometric analysis of cells transfected with EYFP expressing constructs and stained with CaspACE FITC-VAD-FMK. Cell distribution profiles
for HeLa cells transfected with EYFP alone (a), EYFP  Caspace (b, d, and h), His-Vpr  EYFP  Caspace (e), Vpr-EYFP  Caspace (f and j), and VprR73S
 EYFP Caspace (i) are shown as representative. Numbers in each quadrant indicate percentage of cells. Relative Caspace staining is indicated in the histograms
(c, g, and k). (B) The percentage of apoptotic cells in transfected HeLa cells at 72 h posttransfection. HeLa cells, transfected with no DNA (Mock) pEYFP,
pcDNA3.1:Vpr pHis-Vpr, pVpr-EYFP, pEYFP-Vpr, or pcDNA3.1:VprR73S, were stained with CaspACE FITC-VAD-FMK 72 h posttransfection prior to flow
cytometric analysis. Gates were set to measure the amount of CaspACE staining of cells that were positive for expression of either EYFP or a Vpr EYFP fusion
protein. Results shown are representative of three experiments.
Discussion
The use of EGFP/EYFP as fusion partners at the N- or
C-terminus defined Vpr localization in situ to the nucleus
and nuclear membrane, respectively, and allowed coinci-
dent functional analyses. Fusion of Vpr to EGFP or EYFP
at either the N- or the C-terminus affected its ability to arrest
cells in G2/M. Apoptosis induced by both these proteins was
Caspase 3 dependent and independent of coincident cell-
cycle arrest in G2/M.
Using N- and C-terminal GFP (EGFP and EYFP mu-
tants) fusion proteins, we have convincingly shown the
localization of HIV-1 Vpr to be at the nuclear membrane or
in the nuclei of transiently transfected cells, depending upon
the fusion construct. His-tagged Vpr expressed protein pre-
dominantly localized at the nuclear membrane with some
nuclear localization, very similar to the N-terminal fusion
proteins (Vpr-EGFP or Vpr-EYFP). The more diffuse pat-
tern observed with the localization of His-Vpr may be
accounted for by the necessity to permeabilize these cells
prior to staining. Hence, subcellular localization of His-Vpr
could not be visualized under the same physiological con-
ditions as EGFP-Vpr/EYFP-Vpr and Vpr-EGFP/Vpr-
EYFP. The localization pattern for each of the expressed
proteins did not vary significantly between the three cell
lines tested (293T, 293, and HeLa).
Despite Vpr-EGFP, Vpr-EYFP, and His-Vpr all predom-
inantly localizing at the nuclear membrane, only His-Vpr
resulted in sustained arrest of HeLa cells in G2/M. These
results imply that fusion of EGFP to Vpr compromises its
ability to cause sustained G2/M arrest despite a similar
pattern of localization to that of His-Vpr. Interestingly, there
was a transient G2/M arrest observed early after transfection
with the Vpr fusion proteins. Such arrest was unaccompa-
nied by apoptosis (data not shown) and may relate to the
wider distribution of the protein throughout the cell early
after transfection, as opposed to almost exclusive localiza-
tion at the nuclear membrane by 48 h (Figs. 5a and d). Vpr
expressed alone also provided a control that resulted in
similar G2/M arrest to that of His-Vpr. Despite higher levels
of expressed protein for the Vpr fusion proteins as observed
using an anti-Vpr antibody, the effect on cell cycling was
not as marked. These results imply that fusion of EGFP or
EYFP to Vpr compromises its ability to cause sustained
G2/M arrest despite a similar pattern of localization to
His-Vpr.
In contrast to a transient arrest in G2/M for Vpr-EGFP/
Vpr-EYFP and EGFP-Vpr/EYFP-Vpr, particularly in HeLa
cells, the subsequent apoptosis induced was more dramatic
than that observed for either His-Vpr or Vpr alone. Signif-
icantly, higher levels of cell death by apoptosis were in-
duced by Vpr fusion proteins in HeLa cells than by the other
proteins tested, including the Vpr positive control. The level
of apoptosis may be related to differences in the relative
levels of protein expression. The 293 and 293T cells showed
some differences in the extent of apoptosis caused by the
proteins expressed from the various Vpr constructs studied,
but the results were not as marked. The lack of cell-cycle
arrest and lower levels of apoptosis observed in 293 and
293T cells could have been due to the fact that these cells
express the adenovirus E1A and E1B proteins. These may
disrupt the function of Vpr by their actions on p53 and
caspase activation (Hay and Kannourakis, 2002).
In comparison, a mutant Vpr R73S, previously shown to
be expressed at high levels throughout the cell, was com-
promised in both G2/M arrest and induction of apoptosis,
indicating that mutation at position 73 is within a key
functional domain of Vpr, supporting and extending previ-
ous studies showing ablation of cell-cycle arrest (Sawaya et
al., 2000). As this mutation is near the end of the C-terminal
-helix, it may be acting similarly to a H71R mutant pre-
viously described (Chen et al., 1999). Fusion resulted in a
partial loss of Vpr function, whereas mutation resulted in
complete loss of the two functions analyzed. Previous stud-
ies showed that Vpr R73S also had a transdominant nega-
tive effect on transcriptional activation of HIV-1 LTR
(Sawaya et al., 2000).
Several groups have reported Vpr-induced apoptosis
(Jacotot et al., 2000; Shostak et al., 1999; Stewart et al.,
1997, 1999, 2000; Yao et al., 1998), and in some instances
it has been linked to cell-cycle arrest (Stewart et al., 1997;
Watanabe et al., 2000; Yao et al., 1998). We have shown
that expression of Vpr-EGFP/EYFP induced apoptosis in
HeLa cells. This fusion protein localizes to the nuclear
membrane and does not cause sustained cell-cycle arrest.
Based on the apoptosis and cell-cycling results in HeLa
cells, Vpr-induced cell-cycle arrest and apoptosis appear to
be separable functions, as significant levels of apoptosis
were observed coincident with relatively low levels of G2/M
arrest. The lack of apoptosis seen at 24 h posttransfection,
when G2/M arrest was apparent in cells transfected with the
Vpr fusion plasmids, reinforces the independence of these
two Vpr functions (data not shown). This view is supported
by mutational studies by Chen et al. (1999) and Nishizawa
et al. (2000), in which Vpr mutants were able to induce
either G2/M arrest or apoptosis, but not both. The extensive
Caspase 3 dependent apoptosis occurring 72 h posttransfec-
tion coincided with late changes in the localization of each
of the fusion proteins. The apparent perinuclear accumula-
tion and nuclear blebbing may relate to the mechanism of
Vpr-induced apoptosis. This has been shown recently as
Caspase 9 dependent and mitochondrial dependent (Jacotot et
al., 2000; Muthumani et al., 2002). Preliminary studies utiliz-
ing a mitochondrial specific stain of viable cells did not indi-
cate complete colocalization of Vpr fusion proteins and mito-
chondria (M.G. Waldhuber and D.A. McPhee, unpublished
observations). The possible accumulation of Vpr fusion pro-
tein-laden debris in the perinuclear region over time and with
cell division may also be a reason for the large intense areas
observed late after transfection. Perhaps Vpr prevents the nat-
ural cycling of nuclear membrane associated protein(s).
The HIV-1 Vpr protein has two major regions important
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for nuclear localization. These can function independently,
as demonstrated by the use of truncated Vpr constructs
(Jenkins et al., 1998). The first is an N-terminal -helix,
residues 17 to 34 (Mahalingam et al., 1995; Yao et al.,
1995), which forms a nonconventional nuclear localization
signal (NLS) (Karni et al., 1998). Vpr also harbors a second
-helix, residues 53 to 78 (Schuler et al., 1999). Disruption
of this latter domain has been shown to result in the accu-
mulation of Vpr in the nuclear periphery (Subbramanian et
al., 1998). Additionally, the carboxy-terminus of Vpr (aa 73
to 96) contains a bipartite nuclear localization signal (Sher-
man et al., 2001; Zhu et al., 2001). These studies with a
GFP-pyruvate kinase (PK) chimera fused to Vpr (73–96)
showed localization principally in the nucleus. Surprisingly,
a full-length Vpr fusion (GFP-PK-Vpr) protein was almost
exclusively observed in the cytoplasm. Addition of a nu-
clear export inhibitor (leptomycin B) revealed nuclear
shuttling with predominant cytoplasmic localization. In
contrast to cytoplasmic localization of GFP-PK-Vpr (fusion
at the N-terminus of Vpr), a study with EGFP-Vpr (fusion
protein at the N-terminus of Vpr with a flexible linker)
showed nuclear localization. These results are quite similar
to our results with EGFP-Vpr or EYFP-Vpr (fusion to the
N-terminus of Vpr).
Nuclear membrane localization of Vpr has been demon-
strated in studies by Vodicka et al. (1998), similar to the
results shown here for His-Vpr and Vpr fused at the
C-terminus. The presence of Vpr at the nuclear membrane is
consistent with its role in translocation of the preintegration
complex, which may involve association of Vpr with im-
portin- and the nucleoporins (Popov et al., 1998; Vodicka
et al., 1998), or other receptors (Jenkins et al., 1998). The
nuclear membrane localization of Vpr-EGFP was confirmed
from our coincidental studies with His-Vpr and Vpr alone.
Our EGFP-Vpr behaved similarly to Vpr-gal in other stud-
ies where predominant localization in the nucleus, exclud-
ing nucleoli, was observed (Jenkins et al., 1998).
From our studies, it would appear that the localization of
Vpr to the nuclear membrane, as clearly seen with Vpr-
EGFP/EYFP and His-Vpr, is the result of the powerful NLS
at the N-terminus of Vpr. Fusion to GFP at the N- or the
C-terminus differentially affected localization and by infer-
ence probably nucleocytoplasmic shuttling (Sherman et al.,
2001). Fusion to the N-terminus saw efficient transport to
the nucleus, whereas fusion to the C-terminus resulted in
very efficient localization to the nuclear membrane, sug-
gesting rapid uptake and egress from the nucleus resulting
in the accumulation observed. The differences observed
between the nuclear membrane localization of Vpr-EGFP/
EYFP and His-Vpr and the greater predominance of EGFP/
EYFP-Vpr in the nucleus can be explained by the effect of
EGFP/EYFP on the localization of Vpr. Fusion of the pro-
tein to the N-terminus of Vpr appears to attenuate the
function of this NLS. Construction of a C-terminal fusion
protein was designed to avoid any interference with the
N-terminal NLS of Vpr by EGFP/EYFP. Comparison with
the N-terminal fusion protein illustrates how this can be
affected and needs to be taken into account when designing
fusion protein expression vectors. We chose to use EGFP/
EYFP fusion proteins because they are simple and effective
markers for transfected cells, and their use as fusion proteins
circumvents the need for staining with fluorophores or co-
transfection with a marker of efficiency.
There have been various reports regarding any interac-
tion between the subcellular localization of Vpr and its
ability to arrest the cell cycle. Some studies have presented
evidence that the two functions are related, stating that Vpr
must be localized in the nucleus to induce arrest (Chen et
al., 1999; Zhou et al., 1998). However, evidence has also
been presented that Vpr-induced arrest and its subcellular
localization are separate functions so that Vpr mutants that
localize to the cytoplasm are still able to induce arrest
(Mahalingam et al., 1997; Vodicka et al., 1998). In this
study, we have shown that His-Vpr is able to arrest the cell
cycle and cause an accumulation of cells in G2/M when it is
predominantly localized to the nuclear membrane and the
nucleus of transfected cells. However, fusion of Vpr to
EGFP/EYFP attenuates its cell-cycle arrest function, and
this is irrespective of whether the construct is an N- or
C-terminal fusion plasmid. It is possible that the introduc-
tion of a spacer arm between EGFP/EYFP and Vpr may
alleviate the effect EGFP has on Vpr. Therefore, attention
and care must be paid to the design and choice of fusion
constructs and comparison of N- and C-terminal fusion
proteins to ensure no compromise of function. This study
has clearly demonstrated that localization to the nuclear
membrane is not sufficient to cause G2/M arrest. Therefore,
arrest and localization are separate functions of HIV-1 Vpr
and additionally, induction of caspase-dependent apoptosis
is another potentially independent outcome of the effect of
Vpr on the host cell.
Materials and methods
Construction of plasmids
The HIV-1 vpr gene was amplified by PCR from the
molecular clone pNL4-3. The forward 5-G GAA ACT
AAG CTT GCC ACC ATG GAA CAA GCC CCA GAA
G and reverse 5-GG GCT GGA TCC GCG GAT CTA
CTG GCT CCA TTT C primers were designed to incorpo-
rate the restriction enzyme cut sites HindIII and BamHI,
respectively (underlined). The Kozak consensus sequence is
shown in bold. The 319-bp product was digested and cloned
into pEGFP-N1 (Clontech) to obtain Vpr-EGFP. The vpr
open reading frame of HIV-1 NL4-3 was also amplified
with the oligonucleotide primer pair 5-AA CTC GAG TGG
AAC AAG CCC CAG AAG and 5-GG AAG CTT CTA
GGA TCT ACT GGC TCC ATT T to form a 306-bp
product incorporating the XhoI and HindIII restriction sites.
This fragment was cloned into the pEGFP-C1 (Clontech)
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vector to express EGFP-Vpr. For the construction of His-
Vpr, vpr was amplified using the primer pair 5-GGG AAG
CTT GCC ACC ATG CAT CAT CAC CAT CAC CAT
ATG GAA CAA GCC CCA GAA GAC CAA GGG CC and
5- G GGC CTC GAG CTA GGA TCT ACT GGC TCC to
incorporate the HindIII and XhoI restriction sites. The di-
gested 337-bp product was cloned into pcDNA3.1/Myc-
His() A (Invitrogen) to express His-Vpr. The integrity of
all constructs was confirmed by DNA sequencing.
The EGFP coding sequence was cut out of the EGFP-
Vpr and Vpr-EGFP vectors with Age1 and BsrG1 and the
equivalent EYFP (Clontech) sequence inserted. Hence, the
vpr sequence and polylinker were identical.
Cell culture and transfections
The cell lines 293T, 293, and HeLa were grown in
Dulbecco’s modified Eagle’s medium (Gibco-BRL), sup-
plemented with 10% (v/v) heat-inactivated FCS, penicillin
(100 U/ml), streptomycin (100 mg/ml), and L-glutamine
(0.2 mM). Cells were seeded onto coverslips in six-well
plates or into T25 cell-culture flasks and grown until 60–
70% confluent for transfection.
For cells on coverslips, 2.5 g (10 g for flasks) of
plasmid DNA was added to 7.8 l (31 l) of 2 M CaCl2 and
the volume was adjusted to 62.5 l (250 l) with 10 mM
Tris–HCl (pH 7.6). The CaCl2–DNA mix was added to 62.5
l (250 l) of HBS (50 mM HEPES, 1.5 mM Na2HPO4,
280 mM NaCl, pH 7.13) before adding the entire mixture
dropwise to the cell-culture medium. Cells were incubated
at 37°C with 5% CO2. After 16 h, cells were washed twice
with PBS and fresh medium was added before returning the
cells to the incubator until harvested.
Immunoblotting
Cells harvested from flasks were resuspended in 100 l
of lysis buffer (0.5% v/v Nonidet P-40, 0.5% w/v sodium
deoxycholate, 50 mM NaCl, 25 mM Tris–HCl, 10 mM
EDTA, 20 mM phenylmethylsulfonyl fluoride in isopropa-
nol, 0.01% w/v sodium azide, pH 8) and stored at 20°C
until SDS–PAGE was performed using total cell lysates.
Total protein concentrations were calculated by a Brad-
ford’s assay (Bio-Rad) and equal amounts of total protein in
5 loading buffer (10% v/v SDS; 500 mM dTT; 300 mM
Tris, pH 6.8; 0.05% bromphenol blue) were electrophoresed
on 12% SDS–PAGE gels (unless otherwise stated). The
separated proteins were transferred to a Hybond-C Extra
nitrocellulose membrane (Amersham) for analysis by im-
munoblotting. Membranes were blocked for 2 h in 5% w/v
skim milk powder in TBS (0.4 M NaCl, 2.7 mM KCl, 20
mM Tris, pH 8) prior to incubation with either anti-GFP
(Clontech) or anti-Vpr (no. 3252, Contributed by Dr. Vel-
padi Ayyavoo to the AIDS Research and Reference Reagent
Program). Detection was performed using the chemilumi-
nescent ECL system (Amersham).
Confocal microscopy
Cells transfected on coverslips were harvested at 48 h
posttransfection. Cells were rinsed once in PBS and
mounted onto slides with mounting medium (Dako). Images
were collected using a Bio-Rad confocal microscope with
the 60 objective. A Z-series consisting of 15 to 20 sec-
tions, each 0.2 to 0.5 m in thickness, were collected and a
representative section from the cell was selected. To ensure
the selected confocal micrographs were representative, 10 to
12 fields of view (for each construct and each cell line) were
photographed and the percentage of cells exhibiting a par-
ticular localization pattern was determined. Images were
processed using Confocal Assistant (Bio-Rad).
Immunofluorescence studies
293T, 293, and HeLa cells were transfected on cover-
slips. At 48 h posttransfection the cells were washed in PBS,
fixed in 3.5% (w/v) paraformaldehyde/PBS (10 min, RT),
washed with PBS, and permeabilized with methanol:ac-
etone (1:1, 20°C, 10 min). After drying, the cells were
blocked with 1% (w/v) BSA/PBS (10 min, RT) prior to the
addition of the primary antibodies. Cells were incubated at
4°C overnight with rabbit anti-Vpr (1 in 200; no. 3252,
ARRRP) or mouse anti-His (5 g/ml, Boehringer Mann-
heim, USA). Some cells were also incubated with rabbit Ig
or mouse Ig diluted to equivalent concentrations as control
antibodies. All antibodies were diluted in 0.5% (w/v) BSA/
PBS. The cells were washed three times with PBS (5 min
each wash) and incubated for 45 min at RT in the dark with
a 1 in 50 dilution of anti-rabbit FITC or anti-mouse FITC,
as appropriate. The cells were washed three times with PBS
(5 min/wash) prior to mounting on slides and analysis by
confocal microscopy.
Propidium iodide staining and FACS analysis
Harvested cells were pelleted and washed once in PBS
prior to fixing at 1  106 per ml in PBS containing 0.5%
(v/v) formaldehyde and 0.1% (v/v) sodium azide for 1 h at
4°C. Cells were then washed twice in ice-cold PBS and
resuspended in 70% (v/v) ethanol in PBS and incubated
overnight at 4°C to permeabilize the cells. Next, cells were
washed once in PBS and resuspended at a concentration of
1  106 per milliliter containing 5 g/ml RNase (Boehr-
inger Mannheim) and 50 g/ml propidium iodide (Sigma).
Finally, the cells were incubated for 30 min at 37°C and
then stored at 4°C overnight, prior to analysis by FACS
using a Facstar Plus (Becton–Dickinson).
CaspACE FITC-VAD-FMK staining
A fluoroisothiocyanate (FITC) conjugate of the cell-per-
meable caspase inhibitor VAD-FMK, CaspACE FITC-
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VAD-FMK (Promega Corp., USA), binds to activated
caspase and thus acts as an in situ marker for apoptosis.
CaspACE FITC-VAD-FMK assay was carried out as
recommended by the manufacturer. Briefly, 0.5  106 tran-
siently transfected cells were pelleted by centrifugation at
125 g for 5 min at 20°C, then resuspended in 0.1 mL of
DMEM-10 containing 10 M CaspACE FITC-VAD-FMK,
and incubated for 20 min at 37°C in the dark. The cells were
washed three times in PBS and resuspended in 0.5 mL of
3.5% (w/v) paraformaldehyde/PBS and stored at 4°C over-
night. Doubly stained cells were analyzed on a FACStar
Plus flow cytometer and analyzed using Winlist software
(Verify Software House).
As a positive control for apoptosis, Actinomycin D (2.5
and 5 g/mL) was added to the medium of EYFP-trans-
fected cells for 18 h before the cells were harvested and
assayed for caspase activity (Nishizawa et al., 2000). Acti-
nomycin D blocks RNA polymerase II dependent transcrip-
tion by binding to guanine residues in DNA (Herrmann and
Mancini, 2001), thereby inhibiting RNA synthesis and in-
ducing endonuclease activation, hence apoptosis (Martin et
al., 1990).
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